Are Medical Stocks Lagging CVS Health (CVS) This Year?

CVS Health (CVS) has significantly outperformed the broader Medical sector and its specific Medical Services industry year-to-date, posting a 51.8% gain while the sector averaged a 3.9% loss. This strong performance is supported by a Zacks Rank of #2 (Buy) and a 4% increase in its full-year earnings consensus estimate over the past quarter, reflecting improving analyst sentiment. Similarly, Agenus (AGEN) also stands out as a sector outperformer with a 79.2% YTD return and a substantial 124.2% increase in current-year EPS estimates, positioning both companies as notable investments within the medical space.

Analysis

CVS Health (CVS) is demonstrating significant market outperformance, with its stock gaining 51.8% year-to-date, in stark contrast to the broader Medical sector's average loss of 3.9% and its specific Medical Services industry's modest 0.3% gain. This strong relative strength is underpinned by positive fundamental signals, most notably a 4% increase in the consensus full-year earnings estimate over the past quarter, indicating improving analyst sentiment. The stock's Zacks Rank of #2 (Buy) further reinforces this bullish outlook, as the system emphasizes positive earnings estimate revisions as a key driver for near-term (1-3 month) performance. For context, another sector outperformer, Agenus (AGEN), has posted an even more substantial 79.2% year-to-date return, supported by a 124.2% upward revision in its current-year consensus EPS estimate. Both companies stand out as strong performers in a lagging sector, driven by favorable shifts in their earnings outlook.

Key Decisions for Investors

• Given its significant outperformance and positive earnings estimate revisions, investors may consider CVS a strong candidate for a core holding within a diversified healthcare portfolio, representing relative strength in a weak sector.
• The positive momentum in both CVS and Agenus, directly linked to upward earnings revisions and a Zacks #2 (Buy) rating, suggests that investors should prioritize these quantitative signals when screening for opportunities in the Medical sector.
• For those with a higher appetite for momentum, Agenus warrants further due diligence, as its 79.2% year-to-date gain and a dramatic 124.2% increase in EPS estimates signal exceptionally strong investor and analyst sentiment.